INR 383.2
(0.0%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Operating Cash Flow | -174.16 Million | -1.44 Million | 187.68 Million | -62.1 Million | 132.23 Million | 200.94 Million |
Net Income | -323.31 Million | 272.63 Million | 17.82 Million | 63.75 Million | 214.56 Million | 152.25 Million |
Depreciation & Amortization | 17.4 Million | 20.33 Million | 15.1 Million | 23.43 Million | 24.12 Million | 16.16 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | 152.62 Million | -224.4 Million | 132.92 Million | -265.08 Million | -156.41 Million | 40.18 Million |
Other non-cash items | -317.77 Million | -70.01 Million | 21.81 Million | 115.78 Million | 49.95 Million | -7.66 Million |
Investing Cash Flow | 56.86 Million | -38.77 Million | -67.32 Million | -90.11 Million | -293.78 Million | 29.98 Million |
Investments in PPE | -17.28 Million | -3.23 Million | -6.93 Million | -17.7 Million | -25.77 Million | -28.66 Million |
Acquisitions | 276 Thousand | 32.94 Million | 153 Thousand | 229 Thousand | 69.59 Million | 86.34 Million |
Investment purchases | -26.75 Million | -800.36 Million | -294.54 Million | -96.15 Million | -363.97 Million | - |
Sales/Maturities of investments | 100.62 Million | 731.87 Million | 68.28 Million | 43.62 Million | - | 11.01 Million |
Other Investing Activities | -26.75 Million | 1000.00 | 165.72 Million | -20.11 Million | 26.36 Million | -38.7 Million |
Financing Cash Flow | 118.21 Million | -23.77 Million | -65.36 Million | 107.75 Million | 113.06 Million | -298.46 Million |
Debt repayment | -94.28 Million | -3.33 Million | -48.83 Million | -24 Thousand | -1.49 Million | -262.19 Million |
Dividends payments | -13.27 Million | - | - | -25.73 Million | - | -18.09 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | 49.9 Million | -20.43 Million | -16.53 Million | 133.51 Million | 114.56 Million | -18.17 Million |
Accounts receivables | 206.25 Million | -406.65 Million | 61.14 Million | -367.79 Million | 53.77 Million | -235.02 Million |
Accounts payables | 125.45 Million | 213.92 Million | 18.63 Million | 334.69 Million | -114.08 Million | 141.44 Million |
Inventory | - | -127.9 Million | -17.16 Million | -231.98 Million | -96.1 Million | 133.74 Million |
Other working capital | -179.08 Million | 96.22 Million | 70.31 Million | -36.26 Million | - | 16 Thousand |
Cash at beginning of period | 70.73 Million | 134.73 Million | 79.73 Million | 126.91 Million | 175.4 Million | 242.93 Million |
Cash at end of period | 419.94 Million | 70.73 Million | 134.73 Million | 82.44 Million | 126.91 Million | 175.4 Million |
Capital Expenditure | -17.28 Million | -3.23 Million | -6.93 Million | -17.7 Million | -25.77 Million | -28.66 Million |
Effect of forex changes on cash | - | - | - | 1000.00 | -12 Thousand | 9000.00 |
Net cash flow / Change in cash | 349.21 Million | -63.99 Million | 54.99 Million | -44.46 Million | -48.49 Million | -67.53 Million |
Free Cash Flow | -191.44 Million | -4.68 Million | 180.74 Million | -79.8 Million | 106.45 Million | 172.27 Million |
Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -24.83 Million | -160.19 Million | -323.31 Million | -144.94 Million | -34.98 Million | 16.81 Million |
Depreciation & Amortization | - | - | 17.4 Million | 4.87 Million | 4.32 Million | 3.51 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | - | - | 152.62 Million | - | - | - |
Other non-cash items | 24.83 Million | 160.19 Million | -317.77 Million | 144.94 Million | 34.98 Million | -16.81 Million |
Investing Cash Flow | - | - | 56.86 Million | - | - | - |
Investments in PPE | - | - | -17.28 Million | - | - | - |
Acquisitions | - | - | 276 Thousand | - | - | - |
Investment purchases | - | - | -26.75 Million | - | - | - |
Sales/Maturities of investments | - | - | 100.62 Million | - | - | - |
Other Investing Activities | - | - | -26.75 Million | - | - | - |
Financing Cash Flow | - | - | 118.21 Million | - | - | - |
Debt repayment | - | - | -94.28 Million | - | - | - |
Dividends payments | - | - | -13.27 Million | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | - | - | 49.9 Million | - | - | - |
Accounts receivables | - | - | 206.25 Million | - | - | - |
Accounts payables | - | - | 125.45 Million | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | - | - | -179.08 Million | - | - | - |
Cash at beginning of period | - | - | 70.73 Million | 73.02 Million | 108 Million | 70.73 Million |
Cash at end of period | - | - | 419.94 Million | 82.77 Million | 73.02 Million | 16.81 Million |
Capital Expenditure | - | - | -17.28 Million | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | - | 349.21 Million | 9.75 Million | -34.98 Million | -53.92 Million |
Free Cash Flow | - | - | -191.44 Million | 9.75 Million | -34.98 Million | 16.81 Million |
JAGSNPHARM
6262
WEWIN
300042
INNOCORP
PLLTL